Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Eagle Hopes To Build On Bendamustine Success With Injectable Reformulations

Executive Summary

With concentrated, lower-volume injectables, the specialty firm is finding larger patient bases for the cancer drug bendamustine and the muscle relaxant dantrolene.

You may also be interested in...

Eagle flies on Teva bendamustine deal; FDA OK pending

Shares of Eagle Pharmaceuticals soared over 25% on 17 February on word the company had not only kissed and made up with Teva and its subsidiary Cephalon, but had in fact inked a deal involving a rapid infusion form of bendamustine.

Eagle takes sporadic flight on US Ryanodex nod

The FDA granted Eagle Pharmaceuticals approval to market its orphan drug Ryanodex (dantrolene sodium) as a treatment for malignant hyperthermia (MH), an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible people.

Asia Deal Watch: BIOCAD, Shanghai Pharma Agree On Pair Of Russian/Chinese Joint Ventures

The JVs will develop and commercialize therapeutics for multiple cancer types and autoimmune disorders in China. Novocure partners its Tumor Treating Fields technology with Zai Lab, while Fate and ONO will collaborate on off-the-shelf CAR-T therapies.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts